Mouth bacteria may predict colon cancer drug resistance

NCT ID NCT07619859

Ongoing Knowledge-focused Sponsor: Barretos Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines if the amount of a bacteria called Fusobacterium nucleatum in colon cancer tumors is linked to how well patients respond to targeted therapies like cetuximab or panitumumab. Researchers will analyze stored tumor samples from 500 patients with metastatic colorectal cancer. The goal is to understand why some patients do not benefit from these drugs, which could lead to better treatment choices in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients with metastatic colorectal cancer will benefit from anti-EGFR therapies, leading to more personalized treatment.
What could go wrong: This is an observational study, not a treatment trial. It looks at past data, so it can show links but not prove cause and effect. Results may not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Barretos Cancer Hospital

Barretos, São Paulo, 14784-400, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.